EPALINGES, Switzerland – Anergis, a company focusing on proprietary allergy vaccines, reported today that a Phase IIb study of its lead compound AllerT met the primary endpoint of reducing the combined symptom and medication score with AllerT 50 μg during the birch pollen season.
C est un veritable plaisir de lire cette article, je vous en remercie grandement !!!